Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series

References

• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713.
   PubMed Web of Science ®Google Scholar
• Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477–490. doi:10.1080/14712598.2019.1595578.
   PubMed Web of Science ®Google Scholar
• Borekci S, Atahan E, Demir Yilmaz D, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration. 2015;90(3):191–198. doi:10.1159/000434684.
   PubMed Web of Science ®Google Scholar
• By A, Aap T. American thoracic society targeted tuberculin testing and treatment of latent. Crit Care Med. 1999/2000 Apr;1(3):S221–47. doi:10.1164/ajrccm.161.supplement_3.ats600.
   Google Scholar
• Gómez-Reino JJ, Carmona L, Descalzo MÁ. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Care Res. 2007;57(5):756–761. doi:10.1002/art.22768.
   Web of Science ®Google Scholar
• Ozguler Y, Hatemi G, Ugurlu S, et al. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatol Int. 2016;36(12):1719–1725. doi:10.1007/s00296-016-3575-3.
   PubMed Web of Science ®Google Scholar
• Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: Anti-tumor necrosis factor-α and beyond. Clin Chest Med. 2019;40(4):721–739. doi:10.1016/j.ccm.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: A case-control study. Br J Ophthalmol. 2012;96(3):332–336. doi:10.1136/bjophthalmol-2011-300209.
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Smith WM. Intraocular manifestations of mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis. 2017;7:13–21. doi:10.1016/j.jctube.2017.01.003.
   PubMedGoogle Scholar
• La Distia Nora R, Van Velthoven MEJ, Ten Dam-Van Loon NH, et al. Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol. 2014;157(4):754–761. doi:10.1016/j.ajo.2013.11.013.
   PubMed Web of Science ®Google Scholar
• Gupta A, Sharma A, Bansal R, Sharma K. Classification of intraocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1):7–13. doi:10.3109/09273948.2014.967358.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Jones N, Steeples LR. Miliary tuberculosis developing during adalimumab treatment for Behçet’s disease with uveitis. BMJ Case Rep. 2018;11:1. doi:10.1136/bcr-2018-226772.
   Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Shakarchi FI. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 2015;9:2223–2227. doi:10.2147/OPTH.S65254.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Mesquida M, Sainz De La Maza M, et al. Epidemiology of uveitis in a Western urban multiethnic population. the challenge of globalization. Acta Ophthalmol. 2015;93(6):561–567. doi:10.1111/aos.12675.
   PubMed Web of Science ®Google Scholar
• Atlanta GUSD of, Health and Human Services C. CDC. Reported Tuberculosis in the United States, 2002.
   Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Testi I, Mahajan S, et al. The collaborative ocular tuberculosis study (COTS) consensus (CON) group meeting proceedings. Ocul Immunol Inflamm. 2020;1–11. doi:10.1080/09273948.2020.1716025.
   PubMed Web of Science ®Google Scholar
• Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular Tuberculosis-An Update. Surv Ophthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015.
   PubMed Web of Science ®Google Scholar
• Cunningham ET, Rathinam SR, Albini TA, Chee SP, Zierhut M. Tuberculous Uveitis. Ocul Immunol Inflamm. 2015;23(1):2–6. doi:10.3109/09273948.2014.1004016.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24(January):S10–S20. doi:10.1016/j.cmi.2017.12.025.
   PubMedGoogle Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087. doi:10.1016/j.ophtha.2017.12.039.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Cordero-Coma M, Blanco-Esteban A, et al. Drug retention rate and causes of discontinuation of adalimumab in uveitis: real-world data from the biotherapies in uveitis (Bioúvea) study group. Ophthalmology. 2020;2020. doi:10.1016/j.ophtha.2019.11.024.
   Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509. doi:10.1016/j.autrev.2015.01.011.
   PubMed Web of Science ®Google Scholar
• Muñoz L, Casas S, Juanola X, Xavier Bordas C, Martinez MS. Prevention of anti‐tumor necrosis factor associated tuberculosis: A 10‐year longitudinal cohort study. Clin Infect Dis. 2015 Feb 1;60(3):349–356. doi:10.1093/cid/ciu796.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Llorenç V, Artaraz J, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. 2016;36(9):1778–1785. doi:10.1097/IAE.0000000000001001.
   PubMed Web of Science ®Google Scholar
• Hasanreisoglu M, Gulpinar Ikiz G, Aktas Z, Ozdek S. Intravitreal dexamethasone implant as an option for anti-inflammatory therapy of tuberculosis uveitis. Int Ophthalmol. 2019;39(2):485–490. doi:10.1007/s10792-018-0831-4.
   PubMed Web of Science ®Google Scholar